Head & Neck Cancer

FDA grants breakthrough status to Rybrevant Faspro for recurrent or metastatic HPV-negative head and neck cancer after prior therapy.

Overview of diagnosis, stage-based treatments, side effects and follow-up to help patients with cancer understand care choices and expectations.

When most people think about cancer, they think about survival. What they don’t often consider is what survival costs.

“Full House” star Dave Coulier, now undergoing treatment for tongue cancer, sat down for an interview with CURE.

Get expert insight into stage 3 oral cavity cancer, covering diagnosis, multimodal treatment and essential side effect management.

Actor Dave Coulier, best known for his role in the sitcom “Full House,” recently sat down with CURE to discuss facing cancer for the second time.

Six-year phase 3 follow-up showed adding Loqtorzi to chemotherapy nearly doubled survival for recurrent or metastatic nasopharyngeal cancer.

Understand your stage 2 oral cavity cancer diagnosis, explore primary treatment options and get key questions for your oncologist.

In PD-1/PD-L1-pretreated recurrent/metastatic head and neck squamous cell carcinoma buparlisib and paclitaxel was not associated with a survival improvement.

The FDA has granted breakthrough therapy designation to ficerafusp alfa with Keytruda for some patients with head and neck squamous cell carcinoma.

Understand why early detection gives you the best chance, explore your surgery or radiation options, and plan for survivorship with oral cavity cancer.

An LED-based intraoral device was safe and reduced severe oral mucositis and throat pain in patients receiving radiotherapy for head and neck cancers.

The FDA has granted fast track designation to the investigational drug CRB-701 for recurrent or metastatic head and neck squamous cell carcinoma.

This guide for newly diagnosed patients provides key information to help you understand your options and have informed conversations with your oncologist.

In HPV15-positive first-line recurrent and/or metastatic head and neck cancer, PDS0101 and Keytruda elicited median overall survival more than three years.

Greek yogurt, egg salad, avocado and mac and cheese are easy-to-swallow, high-calorie foods that can help patients maintain strength during cancer treatment.

Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free survival versus standard care.

Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell carcinoma of the head and neck.

GLP-1 drugs lowered rates of obesity-related cancers and death versus DPP-4s, with no increased cancer risk, study finds.

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and neck squamous cell carcinoma.

In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 and ASPEN trials.

The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma.

Dr. Zafar Sayed discuss the importance of recognizing Head and Neck Cancer Awareness Month and highlights early symptoms of the disease to be aware of.

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.

Dr. Lillian L. Siu discussed potential risk factors and treatment strategies associated for patients with head and neck cancer.